CME Group (CME) received a buy rating from Erste Group, while Argus Research downgraded its stance to hold, reflecting divergent views on the futures exchange’s near-term outlook and profitability trajectory.
- Erste Group upgraded CME to buy, citing strong market share and operational performance in key derivatives segments.
- Argus Research downgraded CME to hold, citing high valuation and uncertainty around near-term revenue growth.
- CME’s average daily volume in U.S. futures contracts reached 12.7 million contracts in Q4 2025, up 4.1% year-over-year.
- The company reported adjusted EPS of $5.38 for Q4 2025, exceeding analyst estimates by 6.2%.
- CME’s forward P/E ratio stands at 18.3, above the S&P 500 average of 16.7, reflecting premium investor expectations.
- The stock closed at $328.40 on March 10, 2026, up 1.2% on the day, following the ratings update.
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.
Share this article